3-Bomac-btp | 151227-58-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Bomac-btp
• 英文别名: (3R)-N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide
• CAS: 151227-58-6
• 化学式: C₂₀H₁₈N₂O₃S
• 分子量: 366.4
• InChiKey: LJJLQEVGMKLKNY-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  87.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  tert-butyl (3R)-3-(1,3-benzodioxol-5-ylmethylcarbamoyl)-3,4-dihydro-1H-[1]benzothiolo[2,3-c]pyridine-2-carboxylate 以81%的产率得到
  参考文献：
  名称：

  Kawakubo Hiromu, Takagi Seiji, Yamaura Yuuji, Katoh Shinichi, IshimotoYum+, J. Med. Chem, 36 (1993) N 23, S 3526-3532

  摘要：

  DOI：

文献信息

• Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
  申请人：Pharmacia Corporation

  公开号：US20040147581A1

  公开（公告）日：2004-07-29

  Compositions and methods to treat or prevent pain, inflammation, or inflammation-related disorder, as well as a neurologic disorder involving neurodegrneration in a subject that is in need of such prevention or treatment involve a combination of a Cox-2 inhibitor and a 5-HT 1A receptor modulator.

  治疗或预防疼痛、炎症或炎症相关疾病，以及涉及神经退行性的神经系统疾病的组合物和方法，需要在需要预防或治疗的受试者中使用Cox-2抑制剂和5-HT1A受体调节剂。
• 5 HT RECEPTOR MEDIATED NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20100009983A1

  公开（公告）日：2010-01-14

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
• [EN] METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY<br/>[FR] METHODE DE THERAPIE COMBINEE UTILISANT UN INHIBITEUR DE COX-2 ET UN MODULATEUR DU RECEPTEUR 5-HT1A
  申请人：PHARMACIA CORP

  公开号：WO2004045509A2

  公开（公告）日：2004-06-03

  Compositions and methods to treat or prevent pain, inflammation, or inflammation-related disorder, as well as a neurologic disorder involving neurodegrneration in a subject that is in need of such prevention or treatment involve a combination of a Cox-2 inhibitor and a 5-HT1A receptor modulator.